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AbstrACt
background Nivolumab combined with ipilimumab 
have shown activity in melanoma brain metastasis 
(MBM). However, in most of the clinical trials investigating 
immunotherapy in this subgroup, patients with 
symptomatic MBM and/or prior local brain radiotherapy 
were excluded. We studied the efficacy of nivolumab plus 
ipilimumab alone or in combination with local therapies 
regardless of treatment line in patients with asymptomatic 
and symptomatic MBM.
Methods Patients with MBM treated with nivolumab plus 
ipilimumab in 23 German Skin Cancer Centers between 
April 2015 and October 2018 were investigated. Overall 
survival (OS) was evaluated by Kaplan- Meier estimator 
and univariate and multivariate Cox proportional hazard 
analyses were performed to determine prognostic factors 
associated with OS.
results Three hundred and eighty patients were included 
in this study and 31% had symptomatic MBM (60/193 
with data available) at the time of start nivolumab plus 
ipilimumab. The median follow- up was 18 months and 
the 2 years and 3 years OS rates were 41% and 30%, 
respectively. We identified the following independently 
significant prognostic factors for OS: elevated serum 
lactate dehydrogenase and protein S100B levels, 
number of MBM and Eastern Cooperative Oncology 
Group performance status. In these patients treated with 
checkpoint inhibition first- line or later, in the subgroup of 
patients with BRAFV600- mutated melanoma we found no 
differences in terms of OS when receiving first- line either 
BRAF and MEK inhibitors or nivolumab plus ipilimumab 
(p=0.085). In BRAF wild- type patients treated with 
nivolumab plus ipilimumab in first- line or later there was 
also no difference in OS (p=0.996). Local therapy with 
stereotactic radiosurgery or surgery led to an improvement 
in OS compared with not receiving local therapy (p=0.009), 
regardless of the timepoint of the local therapy. Receiving 
combined immunotherapy for MBM in first- line or at a later 
time point made no difference in terms of OS in this study 
population (p=0.119).
Conclusion Immunotherapy with nivolumab plus 
ipilimumab, particularly in combination with stereotactic 
radiosurgery or surgery improves OS in asymptomatic and 
symptomatic MBM.
IntroduCtIon
Melanoma brain metastasis (MBM) is a 
known characteristic for poor prognosis. The 
median overall survival (mOS) in the era of 
chemotherapy was 4 months and decreased 
to 2 months in patients with elevated lactate 
dehydrogenase (LDH).1 2 The response of 
MBM to chemotherapy was approximately 
5%. This applies to both, drugs that cross the 
blood- brain barrier, such as temozolomide 
and fotemustine, and to drugs that do not 
cross the blood- brain barrier, such as dacar-
bazine.3 4 The American Joint Committee 
on Cancer has acknowledged the negative 
impact of brain metastasis on the prog-
nosis of patients with melanoma in its latest 
eighth edition staging system by defining this 
subgroup as M1d.5
With the introduction of targeted treat-
ment (BRAF/MEK inhibitors) and immune 
checkpoint inhibitors, the prognosis of meta-
static melanoma has drastically improved.6–8 
In contrast to ample data on the efficacy of 
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novel therapies in stage IV melanoma without MBM, 
there are only a few small studies on the efficacy of these 
drugs in patients with cerebral disease. This lack of infor-
mation is mainly due to the fact that large phase II/III 
multicenter studies systematically excluded patients with 
MBM, particularly if symptomatic or previously treated 
with local therapy, such as stereotactic radiosurgery and 
surgery (STR/surgery). The first studies investigating 
targeted therapy and immune checkpoint inhibitors in 
patients with MBM showed that these therapies were also 
very effective intracranially.9–12 Currently available data 
suggest that PD-1- based immunotherapy and particularly 
combined immunotherapy with nivolumab and ipilim-
umab (NIVO+IPI) might be more effective than BRAF/
MEK inhibitors.8 13 In two retrospective studies with 
patients with MBM, the authors reported that patients 
receiving immunotherapy had a mOS between 13 and 
14.8 months (95% CI: 8.1 to 17.8 and 9.9 to 19.7, respec-
tively), while in those receiving targeted therapy the mOS 
was only 7 and 10 months (95% CI: 3.8 to 10.2 and 7.8 
to 11.7, respectively).14 15 This difference was also present 
when these systemic therapies were given in combination 
with stereotactic radiosurgery, favoring the combination 
with immunotherapy, which resulted in a mOS between 
21–25 months (95% CI: 12.9 to 29.1 and 14.6 to 35.4, 
respectively) and 12.9–14 months with targeted therapy 
(95% CI: 12.9 to 29.1 and 9.1 to 16.7, respectively).
Our study provides real- world outcome data from 23 
German skin cancer centers, retrospectively assessing the 
activity of NIVO+IPI alone or in combination with local 
therapies regardless of treatment line in patients with 
asymptomatic and symptomatic MBM.
We addressed the following questions: (a) Which prog-
nostic factors for OS can be identified in patients with 
MBM treated with combined immunotherapy? (b) Does 
local therapy (STR/surgery) improves survival in patients 
with MBM treated with NIVO+IPI? (c) Are STR/surgery 
more effective when given before or after combined 
immunotherapy? (d) Is there a difference in terms of 
survival when combined immunotherapy is given as a 
first- line treatment for MBM or later in the course of the 
disease? (e) In patients with BRAF V600- mutated mela-
noma, which first- line systemic therapy for MBM trans-
lates into better OS: first- line immunotherapy or first- line 
targeted therapy? (f) Is there a difference in terms of OS 
when patients with symptomatic and asymptomatic MBM 
receive NIVO+IPI? Since a total of 380 patients were 
included, we were able to perform subgroup analyses with 
reasonable statistical power.
Methods
Patients’ characteristics and treatments
We used pseudo- anonymized forms to document retro-
spective data from patients with MBM treated with 
NIVO+IPI between April 2015 and October 2018. All 
participating centers received the mentioned pseudo- 
anonymized forms including the prespecified information 
to be collected. Data were extracted from patients’ 
medical records in 23 German skin cancer centers either 
by medical doctors or by clinical research documenta-
tion professionals, depending on the site. Patients were 
included regardless of previous local or systemic thera-
pies, provided that they received combined immuno-
therapy for treating MBM.
Multiple MBM were irradiated by whole brain irradia-
tion with opposite lateral field in mask technique. Stereo-
tactic radiosurgery was used to irradiate small brain 
metastasis. Neuroimaging consisted of a stereotactic 
three- dimensional T1- weighted postcontrast Magnetic 
Ressonance Imaging (MRI) acquisition und an planning 
CT scan. Selection of dosimetry parameters (maximum 
dose, marginal isodose and number of isocenters) was 
made according to size, shape, localization and relation-
ship for brain metastasis to critical structures. Target 
localization was referenced to a coordination system and 
target position was tracked during treatment. The data 
cut- off date was October 31, 2018.
statistical Analysis
We performed univariate and multivariate Cox regres-
sion analysis to evaluate the impact of baseline patient 
and disease characteristics on OS. Cox multivariate anal-
ysis included the following factors: sex, BRAF mutation 
status, number of MBM, Eastern Cooperative Oncology 
Group performance status (ECOG- PS) as categorical vari-
ables and age, LDH level and protein S100B level as both 
categorical and numerical variables. The use of cortico-
steroids at the start of combined immunotherapy was also 
documented. As these data are rather complex regarding 
dosage and duration of each individual treatment, they 
will be analyzed in a separate investigation.
OS and follow- up (FU) time were calculated consid-
ering the date of MBM diagnosis and last patient contact 
or death. Kaplan- Meier estimates were used for the calcu-
lation of OS. Differences between groups were assessed 
using the log- rank test. Patients were grouped consid-
ering the timing of combined immunotherapy (first- line 
or not first- line) for treatment of MBM and according 
to BRAF mutation status (BRAFV600 mutant or BRAF 
wild type). Pretreatment protein S100B and LDH values 
were assigned categorical variables (normal, elevated and 
2- fold or 10- fold elevated), according to the institutional 
upper limit of normal. Patients with missing values were 
excluded from the respective analysis. Further subgroups 
considering the number of MBM, presence of neurolog-
ical symptoms and ECOG- PS were defined. To investigate 
the effect of local therapies on OS, data from patients 
receiving STR/surgery were compared with data from 
patients not receiving local therapies. Timing of local 
therapy and its effect on OS were analyzed by defining two 
groups: STR/surgery before start of NIVO+IPI treatment 
or STR/surgery at a later time point. Patients treated 
with whole brain radiotherapy (WBRT) were evaluated 
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Table 1 Patients characteristics of the whole collective (n=380) considering combined immunotherapy at first line or not at 
first line
Baseline characteristics
Total CombiIT first line CombiIT not first line P value*
N (%)
Sex
  Male 240 (63.2) 165 (66) 75 (57.7) 0.111
  Female 140 (36.8) 85 (44) 55 (42.3)
Age (years) at the time of CombiIT
  <54 153 (40.3) 90 (36) 63 (48.5) 0.024
  54–64 105 (27.6) 69 (27.6) 36 (27.7)
  >64 122 (32.1) 91 (36.4) 31 (23.8)
BRAF status
  BRAF wild type 138 (36.3) 112 (44.8) 26 (20) <0.0001
  BRAF mutant 242 (63.7) 138 (55.2) 104 (80)
LDH level†
  Normal 189 (51.4) 131 (54.1) 58 (46.0) 0.223
  Elevated 133 (36.1) 85 (35.1) 48 (38.1)
  2×>ULN 46 (12.5) 26 (10.8) 20 (15.9)
S100B level†
  Normal 109 (32.8) 69 (31.2) 40 (36.4) 0.597
  Elevated 156 (47) 106 (47.7) 50 (45.4)
  10×>ULN 67 (20.2) 47 (21.1) 20 (18.2)
Number of MBM at the time of CombiIT†
  1–3 167 (46.8) 127 (53.6) 40 (33.3) <0.0001
  >3 190 (53.2) 110 (46.4) 80 (66.7)
ECOG- PS†
  0 249 (66.4) 168 (67.7) 81 (63.8) 0.741
  1 87 (23.2) 55 (22.2) 32 (25.2)
  >1 39 (10.4) 25 (10.1) 14 (11)
Presence of symptoms†
  Yes 60 (31) 44 (32.1) 16 (28.6) 0.629
  No 133 (69) 93 (67.9) 40 (71.4)
Local therapy
  STR/surgery‡ 220 (57.9) 135 (54) 85 (65.4) 0.011
  No local therapy 90 (23.7) 71 (28.4) 19 (14.6)
  WBRT 70 (18.4) 44 (17.6) 26 (20)
Bold values indicate statistically significant results.
*Pearson’s χ2 test.
†Denotes variables for which the missing/unknown values were excluded from the analysis.
‡Ten patients (4.5%) received only surgery. Four patients receiving STR/surgery before combined immunotherapy and two patients receiving 
STR/surgery after combined immunotherapy were treated with the two techniques within an interval of 2 weeks.
CombiIT, nivolumab plus ipilimumab; ECOG- PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain 
metastases; n, number of patients in each subgroup; STR, stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain 
radiotherapy.
 o
n
 June 18, 2020 at UB Augsburg. Protected by copyright.
http://jitc.bmj.com/
J Im
m
unother Cancer: first published as 10.1136/jitc-2019-000333 on 26 March 2020. Downloaded from 
4 Amaral T, et al. J Immunother Cancer 2020;8:e000333. doi:10.1136/jitc-2019-000333
Open access 
Table 2 Impact of baseline patient and disease characteristics on overall survival: univariate and multivariate Cox regression 
analysis
Total
N (%)
Univariate analysis
P value
Multivariate 
analysis
P value
HR (death)
(95% CI)
HR (death)
(95% CI
Gender
  Male 240 (63.2) 1 1 0.855
  Female 140 (36.8) 0.94 (0.69 to 1.27) 0.682 1.35 (0.70 to 1.50)
Age (years) at the time of CombiIT   
  <54 153 (40.3) 1 0.616 1 0.689
  54–64 105 (27.6) 1.13 (0.78 to 1.62) 1.17 (0.75 to 1.81) 0.491
  >64 122 (32.1) 1.19 (0.83 to 1.70) 1.20 (0.76 to 1.90) 0.428
BRAF status   
  BRAF wild type 138 (36.3) 1 0.962 1
  BRAF mutant 242 (63.7) 0.99 (0.72 to 1.37) 1.13 (0.76 to 1.67) 0.548
LDH level*   
  Normal 189 (51.4) 1 <0.0001 1 0.069
  Elevated 133 (36.1) 1.24 (0.88 to 1.74) 1.05 (0.69 to 1.59) 0.831
  2×>ULN 46 (12.5) 2.53 (1.67 to 3.83) 1.80 (1.05 to 3.09) 0.031
S100B level*   
  Normal 109 (32.8) 1 0.099 1 0.325
  Elevated 156 (47) 1.35 (0.92 to 2.00) 1.39 (0.90 to 2.11) 0.135
  10×>ULN 67 (20.2) 1.61 (1.02 to 2.54) 1.30 (0.76 to 2.24) 0.341
Number of MBM at the time of CombiIT*   
  1–3 167 (46.8) 1 0.001 1 0.008
  >3 190 (53.2) 1.74 (1.26 to 2.40) 1.67 (1.14 to 2.44)
ECOG- PS*   
  0 249 (66.4) 1 0.001 1 0.006
  1 87 (23.2) 1.3 (0.91 to 1.87) 1.31 (0.87 to 1.99) 0.188
  >1 39 (10.4) 2.58 (1.66 to 4.00) 2.42 (1.39 to 4.20) 0.002
Presence of symptomatic MBM*   
  No 133 (69) 1   
  Yes 60 (31) 1.46 (0.96 to 2.23) 0.078 N/A
Bold values indicate statistically significant results (p<0.05).
*Denotes variables for which the missing/unknown values were excluded from the analysis.
CombiIT, nivolumab plus ipilimumab; ECOG- PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain 
metastases; N 
, number of patients in each subgroup; N/A, not performed for this factor, since information was available to only 50% of the patients; ULN, 
upper level normal.
separately. Results are reported as two- sided p values with 
95% CIs. Statistical significance was set at p<0.05.
results
Patients characteristics
A total of 380 patients with MBM and NIVO+IPI treatment 
were included in the analysis (table 1, online supplemen-
tary figure S1). Thirty- seven per cent of the patients were 
females and median age at the time of MBM diagnosis 
was 58 years (IQR 49–68). The majority of melanomas 
(63.7%) carried a BRAFV600 mutation.
In the univariate Cox regression analysis (table 2), 
we found the following significant prognostic factors 
for OS: LDH level, favoring patients with normal LDH 
(p<0.0001), number of MBM (p=0.001) favoring patients 
with 1–3 MBM and ECOG- PS (p=0.001) favoring patients 
with ECOG- PS=0. No significant OS difference was 
observed for baseline S100B level (p=0.099), BRAFV600 
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mutation status (p=0.962), age groups (p=0.616), sex 
(p=0.682) and presence of symptomatic MBM (p=0.078). 
Multivariate Cox regression analysis using categorical 
variables (table 2) showed that the number of MBM 
(p=0.008) and ECOG- PS (p=0.006) were independent 
prognostic factors for OS. In the multivariate Cox regres-
sion analysis using numerical variables for age, serum 
LDH and protein S100B (online supplementary table 
S4), the following prognostic factors were found to be 
an independently associated with OS: LDH (p=0.001), 
protein S100B (p=0.001), number of MBM (p=0.017) and 
ECOG- PS (p=0.041).
overall survival analysis considering systemic and local 
therapy
The mOS for the whole cohort was 19 months (95% CI: 
15.9 to 22.0) and the median FU time was 18 months 
(IQR 9–28 months). The 1- year, 2- year and 3- year OS 
rates were 69%, 41.1% and 30.1%, respectively (table 3; 
figure 1A; 95% CI: 63.5 to 74.5; 34.9 to 47.9 and 22.2 to 
37.9, respectively).
Figure 1B–E show the Kaplan- Meier OS curves consid-
ering BRAF mutation status, serum LDH level, number 
of MBM, protein S100B level, and online supplementary 
figure S2A–D show the Kaplan- Meier OS curves according 
to age groups, sex, ECOG- PS and presence of symptom-
atic MBM. The results shown are in line with what has 
been previously described in the univariate Cox regres-
sion analysis (table 2), that is, there is a statistically signif-
icant difference between the groups analyzed regarding 
serum LDH level (p<0.0001), number of MBM (p=0.001) 
and ECOG- PS (p<0.0001).
Stratifying for the best intracranial response (figure 1F), 
best OS was observed in patients with complete response 
(CR) and the difference between the subgroups with CR, 
partial response (PR), stable disease (SD) and progressive 
disease (PD) was statistically significant (p<0.0001). The 
mOS for patients with an intracranial CR or SD was not 
reached and for patients with PR and PD was 42 and 10 
months, respectively (table 3; 95% CI: 22.6 to 61.4; 16.7 to 
23.3, respectively). Patients achieving an intracranial CR 
had an improved 1- year OS rate of 92.7% compared with 
those with PD with a 1- year OS rate of only 39% (95% 
CI: 82.9 to 100; 31.4 to 46.6, respectively). Patients with 
SD showed favorable OS that was better than those with 
PR at 2 years and similar to PR at 3 years. The subgroups 
of patients with PR and SD did not differ significantly 
regarding serum LDH level, protein S100B, number of 
MBM, ECOG- PS or presence of extracerebral metastases.
Local therapy (STR/surgery) also improved OS 
(table 3, figure 2A): patients who received local therapy 
(at any time point of the course of the disease) reached a 
mOS of 24 months compared with patients without local 
therapy with only 16 months (p=0.009; 95% CI: 19.6 to 
28.4 and 7.6 to 24.4, respectively). There was no signif-
icant difference in terms of patients’ characteristics in 
these two groups, except for S100B level and presence 
of symptomatic MBM (online supplementary table S1). 
However, we need to acknowledge that information 
regarding the presence of symptomatic MBM was missing 
in approximately 50% of the patients.
When analyzing the time point of local therapy (ie, 
before or after NIVO+IPI), we found no significant differ-
ence in terms of patients’ characteristics (online supple-
mentary table S2) and the mOS was similar in the two 
subgroups (figure 2B; p=0.110). However, there seems to 
be a trend for a benefit of STR/surgery upfront (mOS=26 
months vs 16 months; 95% CI: 21.1 to 30.9; 10.8 to 21.2, 
respectively). Patients who received WBRT had a mOS of 
8 months (table 3, figure 2C; 95% CI: 4.9 to 11.0) and 
were analyzed separately.
No OS difference was observed for patients receiving 
first- line NIVO+IPI compared with those that received 
combined immunotherapy later (figure 2D; p=0.119). 
When looking at the patients’ characteristics from these 
two groups, there was a significant difference between 
them regarding age, BRAFV600 mutation status, number 
of MBM and treatment with local therapy (STR/surgery) 
at the time of starting NIVO+IPI (table 1). These differ-
ences might contribute for similar OS outcomes regard-
less of therapy line.
In the subgroup of patients with BRAFV600 muta-
tion (242 patients), 83 received first- line treatment with 
BRAF/MEK inhibitors, 138 received first- line NIVO+IPI 
and all received combined immunotherapy for MBM in 
the course of the disease. There was no OS difference 
when comparing first- line targeted therapy with first- line 
combined immunotherapy (figure 2E; p=0.085). The 
line of treatment for combined immunotherapy (first- 
line or not first- line) had no effect on survival outcome 
in patients with BRAF wild- type melanoma (figure 2F; 
p=0.996).
Regarding presence of symptomatic MBM, information 
was available for only 193 patients (online supplementary 
figure S2D), but there is a trend benefiting patients with 
asymptomatic MBM (p=0.065). However, if we consider 
only the patients that received first- line NIVO+IPI for 
MBM (n=137), the difference in OS between symptom-
atic and asymptomatic MBM is not significant (p=0.084; 
data not shown).
safety
In the present cohort, a total of 236 (62%) patients were 
reported to have at least one immune- related adverse 
events (irAEs). In 142 (37%) patients, no irAEs were 
documented and there was no available information in 2 
(1%) patients.
We found no difference (Pearson’s χ2 test) in terms of 
onset of irAEs in patients with 1–3 MBM compared with 
patients with >3 MBM (p=0.069). Regarding the onset 
of irAEs in patients who received STR/surgery versus 
those who did not receive STR/surgery, there was also no 
significant difference between the two groups (p=0.657). 
Finally, when analyzing the relation between receiving 
STR/surgery or not, and the interruption of therapy 
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Table 3 Median OS and 1- year, 2- year and 3- year OS rates
mOS (months) (95% CI)
1- year OS
(%; 95% CI)
2- year OS
(%; 95% CI)
3- year OS
(%; 95% CI)
All patients 19 (15.9 to 22.0) 69 (63.5 to 74.5) 41.1 (34.9 to 47.9) 30.1 (22.2 to 37.9)
Number of MBM
  1–3 29 (16.9 to 41.4) 71.2 (63.6 to 78.8) 57.0 (46.8 to 67.2) 42.3 (28.6 to 56.0)
  >3 14 (10.2 to 17.9) 52.1 (44.3 to 59.9) 32.2 (23.9 to 40.4) 22.7 (13.5 to 31.9)
BRAF status
  BRAF wild type 19 (14.9 to 23.0) 61.3 (51.9 to 70.7) 40.1 (28.3 to 51.9) N/A
  BRAF mutant 18 (14.1 to 21.9) 60.7 (53.8 to 67.6) 42.0 (34.2 to 49.8) 27.3 (18.1 to 36.5)
LDH level
  Normal 21 (15.1 to 26.9) 69.3 (61.6 to 76.7) 45.9 (36.3 to 55.5) 32.6 (20.4 to 44.6)
  Elevated 19 (12.8 to 25.1) 58.4 (48.8 to 68.0) 40.1 (29.1 to 51.1) 32.9 (19.9 to 45.8)
  2×>ULN 7 (6.1 to 7.9) 32.1 (17.6 to 46.6) 22.9 (8.0 to 37.8) 8.6 (5.5 to 22.7)
S100B level
  Normal 22 (18.2 to 25.8) 78.4 (68.6 to 88.2) 44.7 (30.8 to 58.6) 36.1 (20.6 to 51.6)
  Elevated 17 (9.6 to 24.4) 57.0 (48.2 to 65.8) 42.8 (32.8 to 52.8) 32.3 (20.5 to 44.6)
  10×>ULN 17 (8.2 to 25.8) 53.5 (40.4 to 66.6) 30.9 (15.8 to 45.9) 20.6 (1.2 to 40.0)
Best intracerebral response
  CR Not reached 92.7 (82.9 to 100) 85.6 (69.3 to 100) N/A
  PR 42 (22.6 to 61.4) 86.9 (76.9 to 96.9) 62.9 (46.0 to 79.8) 55.1 (34.5 to 75.7)
  SD Not reached 93.6 (86.5 to 100) 83.6 (71.1 to 96.1) 50.2 (19.0 to 81.4)
  PD 10 (16.7 to 23.3) 39.0 (31.4 to 46.6) 20.0 (13.1 to 26.9) 12.8 (6.0 to 19.3)
CombiIT
  First line 17 (10.7 to 23.9) 56.4 (48.9 to 63.8) 44.7 (35.9 to 53.5) 27.9 (11.2 to 44.6)
  Not first line 21 (17.8 to 24.2) 67.9 (59.9 to 75.9) 41.9 (32.7 to 51.1) 31.6 (21.8 to 41.4)
BRAF mutant patients     
  First- line targeted therapy 22 (17.2 to 26.77) 65.6 (55.2 to 76) 44.3 (34.5 to 57.7) 32.0 (20 to 44)
  First- line CombiIT 16 (7 to 25) 53.6 (43.2 to 64) 42.9 (30.7 to 55.1) N/A
BRAF wild- type patients     
  First- line CombiIT 21 (10.2 to 31.8) 59.6 (52.6 to 73.4) 47 (33.8 to 60.1) 47 (33.8 to 60.1)
  First- line not CombiIT 19 (16.3 to 21.7) 68.3 (50.1 to 74.2) 31.9 (11.5 to 52.3) 31.9 (11.5 to 52.3)
STR/surgery (at any time 
point)
  Yes 24 (19.6 to 28.4) 70.6 (63.7 to 77.5) 49.5 (40.9 to 58.1) 36.5 (26.3 to 46.7)
  No 16 (7.6 to 24.4) 53.2 (41.0 to 65.4) 40.9 (26.6 to 55.2) N/A
WBRT 8 (4.9 to 11.0) 40.7 (28.4 to 53.0) 20.8 (9.4 to 32.2) 10.4 (1.4 to 22.2)
STR/surgery
  Upfront 26 (21.1 to 30.9) 72.5 (65.1 to 79.9) 50.9 (41.3 to 60.5) 39.5 (28.3 to 50.7)
  Later 16 (10.8 to 21.2) 63.7 (47.6 to 79.8) 44.3 (24.9 to 63.7) 22.2 (1.5 to 45.9)
ECOG- PS
  0 22 (16.4 to 27.6) 65.7 (59.0 to 72.4) 47.1 (39.1 to 55.1) 36.4 (26.4 to 46.4)
  1 18 (7.3 to 28.7) 52.3 (40.1 to 64.5) 38.0 (34.1 to 519) 22.2 (6.1 to 38.3)
  >1 8 (7.3 to 17.1) 49.3 (31.8 to 66.7) 23.5 (5.5 to 41.5) 5.9 (5.1 to 16.9)
Presence of symptomatic 
MBM
    
  No 19 (10.7 to 27.2) 62.5 (53.4 to 71.8) 45.4 (34.6 to 56.2) 35.1 (21.8 to 48.4)
Continued
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mOS (months) (95% CI)
1- year OS
(%; 95% CI)
2- year OS
(%; 95% CI)
3- year OS
(%; 95% CI)
  Yes 12 (7.0 to 17.0) 46 (32.1 to 59.9) 28.1 (13.8 to 42.4) 15.0 (0 to 30.7)
CombiIT, nivolumab plus ipilimumab; CR, complete response; ECOG- PS, Eastern Cooperative Oncology Group performance status; 
MBM, melanoma brain metastases; mOS, median overall survival; PD, progressive disease; PR, partial response; SD, stable disease; STR, 
stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain radiotherapy.
Table 3 Continued
Figure 1 Kaplan- Meier curves for overall survival (A) and 
considering the different factors: (B) BRAF status; (C) LDH 
level; (D) number of melanoma brain metastases (MBM) at 
the time of therapy with nivolumab+ipilimumab; (E) protein 
S100B level; (F) best intracranial response. CR, complete 
response; PD, progressive disease; PR, partial response; SD, 
stable disease.
Figure 2 Kaplan- Meier curves for overall survival (OS) 
according to the following factors: (A) local therapy (STR/
surgery, stereotactic radiosurgery or surgery); (B) time of 
local therapy (before or after combined immunotherapy with 
nivolumab+ipilimumab); (C) for patients receiving whole 
brain radiotherapy (WBRT); (D) combined immunotherapy 
for melanoma brain metastasis (MBM) in first line or later; 
(E) first- line therapy in patients harboring a BRAF mutation 
and (F) combined immunotherapy first line or later in 
BRAF wild- type patients. Patients treated with WBRT were 
excluded from the analysis in figure 2A. Ten patients (4.5%) 
from the STR/surgery group (n=220) received only surgery. 
In the Kaplan- Meier analysis in figure 2B, four patients 
receiving STR/surgery before combined immunotherapy 
and two patients receiving STR/surgery after combined 
immunotherapy were treated with the two techniques in an 
interval of 2 weeks.
due to irAEs, we again found no significant difference 
between the two groups (p=0.913).
dIsCussIon
The present study shows that combined immunotherapy 
with NIVO+IPI can result in improved survival of patients 
with MBM, comparable to results in other stage IV 
patients. This is particularly true if intracranial CR, PR or 
SD has been achieved. The type of intracranial response 
is a strong predictor for OS. In our cohort, the 2- year OS 
rates of patients with SD, PR and CR ranged from 63% 
to 86%, whereas patients with PD had a 2- year OS rate of 
only 20% (table 3). Similar favorable results have been 
reported in the ABC trial, a randomized phase II study 
of nivolumab or NIVO+IPI in patients with MBM.16 The 
3- year intracranial PFS was above 90% for patients with 
asymptomatic, treatment- naïve MBM achieving an intra-
cranial CR, and above 50% for patients with PR. We have 
no explanation why in our cohort patients with SD did 
better than patients with PR.
In our study, the 1- year and 2- year OS rate were 69% 
and 41%, respectively, in line with previous reports.9 10 In 
the already mentioned ABC trial, patients who received 
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combined immunotherapy had a 1- year and 2- year OS 
rate of 63%16 and in the Checkmate-204 trial the reported 
1- year OS rate was even higher (81.5%).10 The survival 
rates in these trials are higher than those reported in 
our cohort. Compared with the ABC trial and the Check-
mate-204 trial, which included patients with asymptom-
atic MBM and treatment- naïve BRAF wild- type patients, 
31% (60/193) of the patients in our trial had symp-
tomatic MBM and 20% of the BRAF wild- type patients 
were pretreated. In the Checkmate-204 trial, 17% of 
the patients had received previous systemic therapy for 
MBM and 52% had only one MBM compared with 34% 
pretreated patients and 53% patients with more than 
three MBM in our cohort.
Two studies evaluating pembrolizumab in patients with 
MBM also reported similar outcomes.17 18 The first study 
evaluated treatment with pembrolizumab monotherapy 
in 23 patients with one or more asymptomatic and 
untreated MBM. With a longer follow- up of 38 months, 
the mOS time was 17 months (95% CI: 10 months to not 
reached) and the 2- year OS was 48%. These are in line 
with our results for patients who did not receive STR/
surgery for whom the mOS was 16 months (95% CI: 7.6 
to 24.4) and the 2- year OS rate was 41%. However, in 
this trial, only asymptomatic patients were included and 
87% had <3 MBM, a population with potentially better 
outcome that the one included in our report. In the 
second study, Anderson et al reported the results of the 
combination from pembrolizumab and radiation therapy 
in 21 patients with MBM. Despite the low number of 
patients included, the percentage of lesions that had a 
CR (>30%), was higher than previously reported with 
systemic therapy or STR alone.
The combination of immunotherapy and local therapy 
with stereotactic irradiation or surgery improved patients’ 
survival compared with patients who only received 
NIVO+IPI. This benefit might be related to a synergic 
effect between radiotherapy and immunotherapy that 
has been demonstrated both in preclinical and clinical 
studies.19–23 The combination of radiation and immune 
checkpoint inhibitors seems to be effective both in the 
irradiated and non- irradiated lesions, and this effect 
might be associated with the activation of cytotoxic T- cells 
and reduction of myeloid- derived suppressor cells.18 24 25
The benefit of combining local and systemic therapy 
in MBM has been previously shown by our group and 
others, with mOS that range from 14 to 25 months and 
1- year OS rates between 58% and 78% in the groups that 
received local and systemic therapy, clearly superior to 
the outcomes of patients receiving only systemic therapy 
(mOS between 6 and 13 months and 1- year OS rates 
ranging from 34% to 53%).14 15 26–33
In our study, the time point at which the patients 
received local therapy did not seem to play a significant 
role in OS: local therapy performed upfront or after initi-
ation of NIVO+IPI resulted in similar OS rates, with a 
trend benefiting local therapy upfront (mOS 26 months 
vs 16 months). Different retrospective studies have also 
addressed this question, and, similar to our cohort, 
upfront local therapy seems to have better outcomes 
(mOS of 11–23 months in the group receiving local 
therapy upfront and 3–9 months in patients receiving 
local therapy after systemic therapy).34 35
There is still an ongoing debate whether some patients 
might be better served with systemic therapy alone, as 
we see very positive outcomes.9–11 36 Not applying local 
therapy reduces local complications, potential cogni-
tive impairment and might be particularly adequate for 
patients with a low number of asymptomatic MBM. This 
question along with the best sequence regarding local 
therapy is being addressed in ongoing clinical trials, and 
in the future, we might be better equipped to decide 
which patients to treat with the different modalities.37 38
In this study, there was a high proportion of patients with 
BRAFV600- mutated melanoma (63%), but similar to other 
publications where this subgroup represents between 52% 
and 65% of the patients.14 15 26 28 Previously, it has been postu-
lated that even in patients with BRAFV600- mutated MBM, 
first- line systemic treatment should consist of combined 
immunotherapy. Our analysis showed that there was no 
difference in OS of patients receiving first- line NIVO+IPI 
or first- line targeted therapy followed by combined immu-
notherapy (p=0.085). The two subgroups did not differ 
significantly (online supplementary table S4), except for 
the number of MBM, where a higher proportion of patients 
with >3 MBM received first- line targeted therapy (p=0.002). 
Our results in this subgroup need to be interpreted with 
caution since we have not included patients with BRAFV600 
mutation who only received targeted therapy.
In the multivariate Cox regression analysis, we identified 
LDH, S- 100B, ECOG- PS and number of MBM as indepen-
dent prognostic factors. These prognostic factors have 
already been described in previous analyses,8 14 39–41 but to 
the best of our knowledge, S100B has only been described 
as independent prognostic factor for checkpoint inhib-
itor immunotherapy in one monocentric study.42 It is 
interesting, however, that both tumor markers, LDH and 
S100B, remained independent prognostic factors in the 
multivariate analysis, suggesting that these non- invasive 
and easy to determine blood parameters can and should 
be used early in the course of the disease to inform about 
patients’ prognosis.
Regarding the presence of symptomatic MBM, there 
was no OS differences between patients with and without 
symptoms (p=0.065), but a trend can be seem showing 
that patients with symptomatic MBM have worse prog-
nosis that those who are asymptomatic (1- year OS rate 
46% and 63%, respectively). In other prospective studies 
investigating similar cohorts, the OS rate ranged from 
66% at 6 months43 to 31% at 12 months.16 Unfortunately, 
information regarding the presence of symptomatic 
MBM is missing in approximately 50% of the patients in 
our study, and therefore, definitive conclusions cannot be 
drawn from our data.
Strengths of this investigation are that data from 23 
German- certified skin cancer centers with high standards 
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for data quality were included. Three- hundred and 
eighty patients were analyzed which is thus far the largest 
published cohort of patients with MBM managed in a 
routine clinical setting. This high number of patients 
allowed us to perform subgroup analyses, with results of 
reasonable sensitivity. Furthermore, this study provides 
long- term follow- up data of patients with MBM covering a 
period of up to 18 months.
The study limitations are related to its retrospective 
design. Patients were included regardless of previous 
systemic and local therapies prior to the combined immu-
notherapy and thus some heterogeneity of the study 
population might have contributed to differences in 
survival outcomes observed in our cohort. The decision 
to offer local therapy or not was probably influenced by 
the number and size of MBM. Additionally, the maximum 
number of MBM considered to be treated individually by 
STR/surgery might vary between different centers. We 
have not evaluated intracranial toxicities. However, this 
aspect might have been considered when planning local 
therapy and targeted therapy in patients with BRAFV600- 
mutated melanoma, influencing the systemic therapy 
offered as well as the therapy sequence in this subgroup.
In conclusion, our study shows that treatment with 
NIVO+IPI, particularly in combination with STR/surgery 
improves survival of patients with MBM. Results presented 
herein also suggest that local therapy with STR/surgery 
either before or after starting combined immunotherapy 
might be advantageous to prolonging OS.
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